Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial

Rigshospitalet

Status and phase: Completed; Early Phase 1

Conditions: Chylothorax; Lymphatic Diseases

Treatments: Drug: Saline infusion; Drug: Octreotide infusion

Study type: Interventional

Funder types: Other

Identifiers

NCT05683444

P-2020-592

Details and patient eligibility

About

This study aims to investigate whether octreotide, a medication used off-label to treat chylothorax, has a direct effect on human lymphatic drainage. To study the effects of octreotide, the researchers conducted a pre-clinical experiment using human lymphatic vessels mounted in a myograph chamber and a clinical experiment in which a double-blinded, randomized, cross-over trial was conducted in 16 healthy adults. The results of the study will be used to determine the role of octreotide in the treatment of chylothorax and other lymphatic disorders.

Full description

This study aimed to investigate whether octreotide, a medication used off-label to treat chylothorax, has a direct effect on human lymphatic drainage. Chylothorax is a condition in which there is an accumulation of lymphatic fluid in the chest cavity, and the mechanism through which octreotide helps to resolve this condition is not well understood. It has been speculated that the drug may reduce lymph production, but this has not been directly demonstrated. To study the effects of octreotide on human lymphatic vessels, the investigators conducted two experiments: a pre-clinical experiment using human lymphatic vessels mounted in a myograph chamber, and a clinical experiment in which a double-blinded, randomized, cross-over trial was conducted in 16 healthy adults, assessed by using plethysmography and near-infrared fluorescence imaging. The results of the study will be used to determine the role of octreotide in the treatment of chylothorax and to clarify the mechanism through which it acts. It is important to continue researching and developing effective treatments for chylothorax, as it can be a difficult condition to manage and may cause serious complications if left untreated.

Enrollment: 16 patients

Sex: All

Ages: 20 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

* Healthy

Exclusion criteria

• No daily medication (except birth control), or allergies towards contrast agents.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

16 participants in 2 patient groups

Healthy participant 1

Other group

Treatment:

Drug: Octreotide infusion

Drug: Saline infusion

Healthy participant 2

Other group

Treatment:

Drug: Octreotide infusion

Drug: Saline infusion